에서 실시간으로 운영 중이에요! 자세히 알아보기

Omeros

OMER

시가총액 US$11.7억

16.20 USD

-2.59

13.78%

장 마감 시점 업데이트됨 10월 16일 PM 4:00 EDT

프리마켓

시간외 거래

16.25

+0.05

0.31%

1일

-13.78%

5일

-17.93%

1개월

-6.57%

3개월

75.7%

6개월

29.19%

연초 이후

-1.1%

1년

64.8%

5년

185.71%

10년

113.16%

소개: Omeros Corp is an inventive, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The company's clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program.

직원 수: 175

건강관리 생명공학

뉴스

긍정적

중립

부정적

투자 심리 3개월

긍정적 37.5%

중립 56.3%

부정적 6.3%

Omeros Stock Sinks on Negative EU Opinion for Narsoplimab, Compassionate-Use Program Ends

Omeros Corporation (NASDAQ:OMER) shares are trading lower Friday after the company announced that the European Medicines Agency's CHMP issued a negative opinion on its marketing authorization application for narsoplimab in TA-TMA, following re-examination of its original negative opinion from June.

Omeros Stock Sinks on Negative EU Opinion for Narsoplimab, Compassionate-Use Program Ends

Omeros Corporation Receives CHMP Negative Opinion Following Re-Examination of European Marketing Authorization Application for Narsoplimab in TA-TMA

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a negative opinion on the company's marketing authorization application (MAA) for narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA) following re-examination of its original negative opinion adopted in June 2026. An eight-member ad hoc expert group (.

Omeros Corporation Receives CHMP Negative Opinion Following Re-Examination of European Marketing Authorization Application for Narsoplimab in TA-TMA

Omeros Transplant Drug Could Be Bigger than Expected, Says Analyst

Cantor Fitzgerald on Tuesday upgraded Omeros Corp (NASDAQ:OMER), citing a better-than-expected Yartemlea launch.

Omeros Transplant Drug Could Be Bigger than Expected, Says Analyst

Zacks Investment Research

What Makes Omeros (OMER) a Strong Momentum Stock: Buy Now?

Does Omeros (OMER) have what it takes to be a top stock pick for momentum investors? Let's find out.

What Makes Omeros (OMER) a Strong Momentum Stock: Buy Now?

Zacks Investment Research

Omeros (OMER) Just Flashed Golden Cross Signal: Do You Buy?

Omeros Corporation (OMER) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, OMER's 50-day simple moving average crossed above its 200-day simple moving average, known as a "golden cross.

Omeros (OMER) Just Flashed Golden Cross Signal: Do You Buy?

Investors Business Daily

This Biotech Stock Just Gapped Up To A Five-Year High; Here's Why

Omeros stock rocketed to a five-year high Thursday on blowout second-quarter results for its new treatment for transplant complications.

This Biotech Stock Just Gapped Up To A Five-Year High; Here's Why

Omeros Corporation (OMER) Q2 2026 Earnings Call Transcript

Omeros Corporation (OMER) Q2 2026 Earnings Call Transcript

Omeros Corporation (OMER) Q2 2026 Earnings Call Transcript

Omeros Q2 Earnings Call Highlights

Omeros NASDAQ: OMER reported second-quarter net sales of $28.5 million for YARTEMLEA, its newly launched treatment for hematopoietic stem cell transplant-associated thrombotic microangiopathy, or TA-TMA, as the company generated positive operating cash flow and reduced its convertible debt after the quarter ended.

Omeros Q2 Earnings Call Highlights

Zacks Investment Research

Omeros (OMER) Q2 Earnings and Revenues Beat Estimates

Omeros (OMER) came out with quarterly earnings of $0.02 per share, beating the Zacks Consensus Estimate of a loss of $0.27 per share. This compares to a loss of $0.53 per share a year ago.

Omeros (OMER) Q2 Earnings and Revenues Beat Estimates

Omeros Corporation Reports Second Quarter 2026 Financial Results

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced recent highlights and developments as well as financial results for the second quarter ended June 30, 2026, which include: Second Quarter and Recent Highlights YARTEMLEA®, the first and only approved treatment for stem cell transplant-associated thrombotic microangiopathy (TA-TMA), an often-lethal complication of stem cell transplantation, generated gross revenues of $32.2 million in the second quarter of 2026, an incre.

Omeros Corporation Reports Second Quarter 2026 Financial Results

뉴스 순위 보기

Lightweight Charts™를 사용해 가격 차트를 구현했어요.